Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Sutro Biopharma Analyst Ratings and Price Targets | NASDAQ:STRO | Benzinga
Sutro Biopharma Inc has a consensus price target of $6.68 based on the ratings of 11 analysts. The high is $17 issued by JMP Securities on December 11, 2024. The low is $0.8 issued by B of A Securities on May 19, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, B of A Securities, and HC Wainwright & Co. on June 16, 2025, May 19, 2025, and April 29, 2025, respectively. With an average price target of $1.6 between Piper Sandler, B of A Securities, and HC Wainwright & Co., there's an implied 75.36% upside for Sutro Biopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
B of A Securities
HC Wainwright & Co.
HC Wainwright & Co.
Wedbush
1calculated from analyst ratings
Analyst Ratings for Sutro Biopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/16/2025 | Buy Now | 119.2% | Piper Sandler | Edward Tenthoff52% | $2 → $2 | Upgrade | Neutral → Overweight | Get Alert |
| 05/19/2025 | Buy Now | -12.32% | B of A Securities | Tazeen Ahmad56% | $1 → $0.8 | Maintains | Underperform | Get Alert |
| 04/29/2025 | Buy Now | 119.2% | HC Wainwright & Co. | Andres Maldonado48% | $2 → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 03/17/2025 | Buy Now | 119.2% | HC Wainwright & Co. | Andrew Fein62% | $12 → $2 | Downgrade | Buy → Neutral | Get Alert |
| 03/14/2025 | Buy Now | — | Citizens Capital Markets | Reni Benjamin49% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 03/14/2025 | Buy Now | 119.2% | Wedbush | David Nierengarten62% | $8 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 03/14/2025 | Buy Now | 9.6% | B of A Securities | Tazeen Ahmad56% | $11 → $1 | Downgrade | Buy → Underperform | Get Alert |
| 12/11/2024 | Buy Now | 338.4% | Wells Fargo | — | $5 → $4 | Maintains | Equal-Weight | Get Alert |
| 12/11/2024 | Buy Now | 1763.22% | JMP Securities | Reni Benjamin49% | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/18/2024 | Buy Now | 1215.21% | HC Wainwright & Co. | Andrew Fein62% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 10/11/2024 | Buy Now | 1105.61% | Piper Sandler | Edward Tenthoff52% | $11 → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 10/11/2024 | Buy Now | 1215.21% | HC Wainwright & Co. | Andrew Fein62% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 1763.22% | JMP Securities | Reni Benjamin49% | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/16/2024 | Buy Now | 1215.21% | HC Wainwright & Co. | Andrew Fein62% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 1544.02% | Truist Securities | Asthika Goonewardene43% | $18 → $15 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | 1215.21% | HC Wainwright & Co. | Andrew Fein62% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 996.01% | Oppenheimer | Jay Olson60% | $10 → $10 | Maintains | Outperform | Get Alert |
| 05/14/2024 | Buy Now | 1215.21% | HC Wainwright & Co. | Andrew Fein62% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 776.81% | Wedbush | David Nierengarten62% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 05/08/2024 | Buy Now | 1215.21% | B of A Securities | Tazeen Ahmad56% | → $12 | Initiates | → Buy | Get Alert |
| 04/03/2024 | Buy Now | 1763.22% | JMP Securities | Reni Benjamin49% | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/03/2024 | Buy Now | 1105.61% | Piper Sandler | Edward Tenthoff52% | $12 → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | Buy Now | 996.01% | Oppenheimer | Jay Olson60% | $10 → $10 | Maintains | Outperform | Get Alert |
| 04/03/2024 | Buy Now | 1872.82% | Truist Securities | Asthika Goonewardene43% | $25 → $18 | Maintains | Buy | Get Alert |
| 03/28/2024 | Buy Now | 996.01% | Oppenheimer | Jay Olson60% | → $10 | Maintains | Outperform | Get Alert |
| 03/27/2024 | Buy Now | 996.01% | Oppenheimer | Jay Olson60% | $10 → $10 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 1763.22% | JMP Securities | Reni Benjamin49% | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/26/2024 | Buy Now | 776.81% | Wedbush | David Nierengarten62% | $12 → $8 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 1215.21% | HC Wainwright & Co. | Andrew Fein62% | $16 → $12 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 1215.21% | Piper Sandler | Edward Tenthoff52% | $18 → $12 | Maintains | Overweight | Get Alert |
| 11/14/2023 | Buy Now | 1653.62% | HC Wainwright & Co. | Andrew Fein62% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | 1215.21% | Deutsche Bank | James Shin52% | → $12 | Initiates | → Buy | Get Alert |
| 10/23/2023 | Buy Now | 1215.21% | Wedbush | David Nierengarten62% | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 10/06/2023 | Buy Now | 996.01% | Oppenheimer | Jay Olson60% | → $10 | Initiates | → Outperform | Get Alert |
| 09/06/2023 | Buy Now | 2640.03% | Truist Securities | Asthika Goonewardene43% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 1763.22% | JMP Securities | Reni Benjamin49% | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/11/2023 | Buy Now | 1653.62% | HC Wainwright & Co. | Andrew Fein62% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 1215.21% | Wedbush | David Nierengarten62% | $20 → $12 | Maintains | Outperform | Get Alert |
| 06/27/2023 | Buy Now | 1763.22% | JMP Securities | Reni Benjamin49% | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/12/2023 | Buy Now | 1763.22% | JMP Securities | Reni Benjamin49% | → $17 | Reiterates | → Market Outperform | Get Alert |
| 05/17/2023 | Buy Now | 1763.22% | JMP Securities | Reni Benjamin49% | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/16/2023 | Buy Now | 1653.62% | HC Wainwright & Co. | Andrew Fein62% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2023 | Buy Now | 1763.22% | JMP Securities | Reni Benjamin49% | $20 → $17 | Maintains | Outperform | Get Alert |
| 03/31/2023 | Buy Now | 2092.02% | Wedbush | David Nierengarten62% | → $20 | Reiterates | → Outperform | Get Alert |
| 03/31/2023 | Buy Now | 1653.62% | HC Wainwright & Co. | Andrew Fein62% | $20 → $16 | Maintains | Buy | Get Alert |
| 01/13/2023 | Buy Now | 2640.03% | Truist Securities | Asthika Goonewardene43% | $21 → $25 | Maintains | Buy | Get Alert |
| 01/10/2023 | Buy Now | 1872.82% | Piper Sandler | Edward Tenthoff52% | $16 → $18 | Maintains | Overweight | Get Alert |
| 11/09/2022 | Buy Now | 2092.02% | HC Wainwright & Co. | Andrew Fein62% | $30 → $20 | Maintains | Buy | Get Alert |
| 08/23/2022 | Buy Now | 2201.62% | Truist Securities | Asthika Goonewardene43% | $37 → $21 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Sutro Biopharma (STRO) stock?
The latest price target for Sutro Biopharma (NASDAQ:STRO) was reported by Piper Sandler on June 16, 2025. The analyst firm set a price target for $2.00 expecting STRO to rise to within 12 months (a possible 119.20% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sutro Biopharma (STRO)?
The latest analyst rating for Sutro Biopharma (NASDAQ:STRO) was provided by Piper Sandler, and Sutro Biopharma upgraded their overweight rating.
When was the last upgrade for Sutro Biopharma (STRO)?
The last upgrade for Sutro Biopharma Inc happened on June 16, 2025 when Piper Sandler raised their price target to $2. Piper Sandler previously had a neutral for Sutro Biopharma Inc.
When was the last downgrade for Sutro Biopharma (STRO)?
The last downgrade for Sutro Biopharma Inc happened on March 17, 2025 when HC Wainwright & Co. changed their price target from $12 to $2 for Sutro Biopharma Inc.
When is the next analyst rating going to be posted or updated for Sutro Biopharma (STRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sutro Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sutro Biopharma was filed on June 16, 2025 so you should expect the next rating to be made available sometime around June 16, 2026.
Is the Analyst Rating Sutro Biopharma (STRO) correct?
While ratings are subjective and will change, the latest Sutro Biopharma (STRO) rating was a upgraded with a price target of $2.00 to $2.00. The current price Sutro Biopharma (STRO) is trading at is $0.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
